Clavis Pharma licenses improved gemcitabine candidate to Clovis Oncology
24 November 2009
Sukaina Virji
Please Login to read the full article.
24 November 2009
Sukaina Virji
sukaina.virji@informa.com
Clavis Pharma of Norway has licensed its anticancer candidate CP-4126 to US-based Clovis Oncology in a deal worth up to $380 million, including $15 million up front.
CP-4126, the second programme in Clavis's pipeline, is a lipid-conjugated form of gemcitabine. An intravenous formulation is...
Please Login to read the full article.
RELATED CONTENT
FEATURES
Other Informa Features
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
